Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive?Zacks Investment Research • 01/24/24
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia GravisPRNewsWire • 01/18/24
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?Zacks Investment Research • 01/17/24
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PRNewsWire • 01/16/24
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer TypesPRNewsWire • 01/16/24
Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?Zacks Investment Research • 12/06/23
Can Halozyme Therapeutics (HALO) Climb 28.72% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 11/16/23
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia GravisPRNewsWire • 11/16/23
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's DiseasePRNewsWire • 11/06/23
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell CarcinomaPRNewsWire • 10/19/23
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery ConferencePRNewsWire • 10/16/23
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug DeliveryPRNewsWire • 10/16/23